


Application No. 10/645,312
 Amendment dated February 16, 2006
 After Allowance Under 37 C.F.R. 1.312

Docket No.: 58288(72021)

AMENDMENTS TO THE CLAIMS

1. (Previously presented) A compound of the Formula:



or a pharmaceutically acceptable salt thereof, wherein:

G is oxygen or NH;

Rx is straight or branched chain C₁₋₈alkyl;

R₁ and R₃ are independently selected from hydrogen, cyano, C₁₋₄alkyl, halogen, C₁₋₂haloalkyl,

C₁₋₂haloalkoxy, mono- and di-C₁₋₄alkylamino, C₁₋₄alkoxy, and C₁₋₄alkylthio;

R₅ is hydrogen, halogen, hydroxy, C₁₋₄alkyl, or C₁₋₄alkoxy;

K is N or CH;

R₇ is halogen, cyano, C₁₋₄alkyl, C₁₋₂haloalkyl, C₁₋₂haloalkoxy, mono- and di-C₁₋₄alkylamino, C₁₋₂alkoxyC₁₋₄alkyl, C₁₋₂alkoxycarbonyl, mono- and di-C₁₋₂alkylcarboxamido, -C(=O)NH₂, hydroxyC₁₋₂alkyl, trifluoromethylsulfonyl, 2,2,2-trifluoro-1-hydroxyethyl, or a 4-7 member heterocycloalkyl group containing 1 or 2 atoms independently chosen from N, O, and S;

R₈ is halogen, hydroxy, C₁₋₂alkyl, C₁₋₂alkoxy, or mono- and di-(C₁₋₂alkyl)amino.

2. (Original) A compound or salt according to Claim 1 wherein R₁ and R₃ are not hydrogen.

- 3-4. (Canceled).

5. (Original) A compound or salt according to Claim 1 wherein G is NH and Rx is 1-ethyl propyl.

Application No. 10/645,312
Amendment dated February 16, 2006
After Allowance Under 37 C.F.R. 1.312

Docket No.: 58288(72021)

6. (Original) A compound or salt according to Claim 5 wherein R₁ is cyano, methoxy, or methylthio and R₃ is methyl or ethyl.

7. (Original) A compound or salt according to Claim 1 wherein G is oxygen and R_x is 1-ethylpropyl, 1-isopropyl-2-methypropyl, 1-propylbutyl, or 1-ethylbutyl.

8. (Original) A compound or salt according to Claim 7 wherein R₃ is halogen, C₁₋₂alkyl, or methylamino.

9. (Original) A compound or salt according to Claim 7 wherein R₁ is halogen, methyl, methoxy, ethyl, ethoxy, or C₁₋₂alkylamino.

10. (Original) A compound or salt according to Claim 7 wherein R₁ is methylamino.

11. (Cancelled).

12. (Original) A compound or salt according to Claim 1 wherein, in a standard in vitro CRF receptor binding assay the compound exhibits a K_i value for CRF receptors of less than or equal to 1 micromolar.

13. (Original) A compound or salt according to Claim 1 wherein, in a standard in vitro CRF receptor binding assay the compound exhibits a K_i value for CRF receptors of less than or equal to 100 nanomolar.

14. (Original) A compound or salt according to Claims 1 wherein, in a standard in vitro CRF receptor binding assay, the compound exhibits a K_i value for CRF receptors of less than or equal to 10 nanomolar.

Application No. 10/645,312
Amendment dated February 16, 2006
After Allowance Under 37 C.F.R. 1.312

Docket No.: 58288(72021)

15. (Previously presented) A method for treating anxiety, or depression, comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound or salt according to Claim 1.

16. (Canceled)

17. (Original) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound or salt of Claim 1.

18. (Previously presented) A pharmaceutical composition according to Claim 17, wherein the composition is formulated as an injectable fluid, an aerosol, a cream, a gel, a tablet, a capsule, a syrup or a transdermal patch.

19. (Previously presented) A package comprising a pharmaceutical composition of Claim 17 in a container and further comprising indicia comprising at least one of:

instructions for using the composition to treat a patient suffering from anxiety, or instructions for using the composition to treat a patient suffering from depression.

20-26. (Canceled).